Welcome to our dedicated page for Kura Oncology SEC filings (Ticker: KURA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Kura Oncology, Inc. filings document a Nasdaq-listed biopharmaceutical company focused on precision medicines for cancer, including disclosures on KOMZIFTI™ (ziftomenib), acute myeloid leukemia programs, darlifarnib (KO-2806) and collaboration activity with Kyowa Kirin. Form 8-K reports cover financial results, FDA approval and product-launch disclosures, clinical program updates, milestone payments and other material events.
Governance filings include the company’s definitive proxy statement for annual meeting matters, director elections, auditor ratification and executive compensation. Other filings describe amendments to bylaws, the 2023 Inducement Option Plan, nonstatutory stock option grants and the company’s common stock listing on The Nasdaq Global Select Market.
Kura Oncology, Inc. Chief Commercial Officer Brian T. Powl reported an open-market sale of 339 shares of common stock at $9.21 per share. The transaction was carried out under a pre-arranged Rule 10b5-1 trading plan. Following this sale, he directly holds 183,614 shares of Kura Oncology common stock.
Kura Oncology, Inc. Chief Operating Officer Kathleen Ford reported an open-market sale of 2,257 shares of common stock on May 19, 2026 at a weighted average price of $9.0752 per share. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on August 29, 2025.
According to the filing, the 2,257 shares sold match 2,257 shares acquired on May 17, 2026 through the company’s Employee Stock Purchase Plan. After this transaction, Ford directly holds 153,560 shares of Kura Oncology common stock.
Kura Oncology, Inc. Chief Legal Officer Teresa Brophy Bair sold 2,256 shares of common stock in an open-market transaction at a weighted average price of $9.3795 per share. The sale was made under a pre-arranged Rule 10b5-1 trading plan adopted on September 4, 2025.
According to the filing, the 2,256 shares sold had been acquired on May 17, 2026 through the company’s Employee Stock Purchase Plan. Following this transaction, Bair directly holds 226,931 shares of Kura Oncology common stock.
Armistice Capital, LLC and Steven Boyd filed Amendment No. 5 to a Schedule 13G/A reporting shared beneficial ownership of 3,736,000 shares of Kura Oncology common stock, equal to 4.23% (03/31/2026). The filing states Armistice Capital is the investment manager of Armistice Capital Master Fund Ltd., the direct holder, and that the Master Fund disclaims beneficial ownership by reason of its Investment Management Agreement with Armistice Capital.
Kura Oncology reported first-quarter 2026 results showing its transition into a commercial-stage company. Total revenue reached $18.3 million, including $5.8 million in net product revenue from KOMZIFTI, its newly launched AML drug, and $12.5 million of collaboration revenue from the Kyowa Kirin partnership.
The company’s operating expenses rose with commercialization and late-stage development, driving a net loss of $73.3 million, or $0.83 per share. Research and development spending was $65.3 million and selling, general and administrative expenses were $31.6 million, reflecting expanding clinical programs and commercial infrastructure.
Kura ended March 31, 2026 with $580.8 million in cash, cash equivalents and short-term investments and contract liabilities of $464.4 million related mainly to the Kyowa Kirin agreement. Management believes this cash, combined with expected partnership payments, can fund its operating plan into the fourth quarter of 2027 and through initial Phase 3 ziftomenib readouts anticipated in 2028.
Kura Oncology reported first quarter 2026 results highlighted by the first commercial sales of KOMZIFTI, its menin inhibitor for relapsed or refractory NPM1‑mutated AML. KOMZIFTI generated $5.8 million in net product revenue, with 85 new patient starts, 157 total prescriptions and more than 93% payer coverage.
Total revenue was $18.3 million, up from $14.1 million a year earlier, driven by new product revenue and $12.5 million of collaboration revenue. Kura posted a net loss of $73.3 million as it increased R&D and commercialization spending. Cash and investments of $580.8 million, plus $180 million in anticipated collaboration payments, are expected to fund its ziftomenib AML program through topline Phase 3 KOMET‑017 results anticipated in 2028.
Vanguard Capital Management reports beneficial ownership of 4,428,812 shares of Kura Oncology common stock, representing 5.01% of the class as of 03/31/2026. The filing shows sole dispositive power over 4,428,812 shares and sole voting power for 643,127 shares. The filing states these holdings include securities held by Vanguard funds and certain affiliates and that no other single person’s interest exceeds 5%.